SCHEMBL30769645

SCHEMBL30769645

CC(C)(C)OC[C@H]1C(=O)N2CCOCC2C(=O)N1Cc1ccncc1

nearest known ligand 0.31

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PDE1A P54750 2/20 0.31
PDE1B Q01064 2/20 0.31
PDE1C Q14123 2/20 0.31
HDAC6 Q9UBN7 1/20 0.31
PIK3C3 Q8NEB9 1/20 0.31
GPR84 Q9NQS5 1/20 0.31
GRM2 Q14416 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
HCRTR1 O43613 1/20 0.31
HCRTR2 O43614 1/20 0.31
KDM4E B2RXH2 1/20 0.31
ALDH1A1 P00352 1/20 0.31
GAA P10253 1/20 0.31
MAPT P10636 1/20 0.30
PRKDC P78527 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31473135 0.90 RIPK1 (0.34) HDAC6PIK3C3MEN1KMT2AHCRTR1
SCHEMBL31757976 0.82 GSK3B (0.32) HDAC6GRM2HCRTR1HCRTR2MAPT
SCHEMBL31473146 0.81 GAA (0.33) ALDH1A1GAA
SCHEMBL31473149 0.73 KMT2A (0.42) MEN1KMT2AHCRTR1HCRTR2KDM4E
SCHEMBL31758029 0.72 PLA2G10 (0.37) HDAC6MEN1KMT2AHCRTR1HCRTR2
SCHEMBL303241 0.71 EHMT2 (0.38) PIK3C3MEN1KMT2ATDP1KDM4E
SCHEMBL31473165 0.66 ITGB3 (0.35) HDAC6PIK3C3ALDH1A1
SCHEMBL31436236 0.62 CMA1 (0.51) PDE1APDE1BPDE1CMEN1KMT2A
SCHEMBL31473158 0.62 EHMT2 (0.40) HDAC6
SCHEMBL14172061 0.62 GRM2 (0.39) GRM2MEN1KMT2AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260008784-A1 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR MEDICAL USE FOR THE TREATMENT OR PREVENTION OF VASCULAR DISEASES VASTHERA CO LTD (KR) 2026-01-08 US disclosed
EP-4547673-A1 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR MEDICAL USE FOR THE TREATMENT OR PREVENTION OF VASCULAR DISEASES VASTHERA Co. Ltd. (KR) 2025-05-07 EP disclosed
CN-119403810-A Compounds, pharmaceutical compositions containing them and their medical use for the treatment or prevention of vascular diseases 瓦斯塞拉股份有限公司 2025-02-07 CN disclosed
WO-2024005556-A1 Compounds, pharmaceutical compositions containing them and their medical use for the treatment or prevention of vascular diseases VASTHERA CO., LTD. (KR) 2024-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260008784-A1 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR MEDICAL USE FOR THE TREATMENT OR PREVENTION OF VASCULAR DISEASES PRDX1, PRDX2, PRDX6 PDE1A 1620/4885PDE1B 1610/4885PDE1C 1622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.